MDxHealth (NASDAQ:MDXH) Trading Up 0.4% - Here's Why

Key Points

• MDxHealth shares increased by 0.4%, closing at $4.65 with a trading volume of over 214,000 shares, marking a 20% rise from the average.
• Equities research analysts maintain a consensus rating of “Buy” for MDxHealth, setting a target price of $7.00 after a positive review from Craig Hallum and Wall Street Zen.
• MDxHealth reported an earnings miss with an EPS of ($0.15), falling short of the expected ($0.13), alongside revenues that matched analyst estimates at $26.60 million.

Shares of MDxHealth SA (NASDAQ:MDXH - Get Free Report) were up 0.4% on Monday . The company traded as high as $4.68 and last traded at $4.65. Approximately 214,514 shares traded hands during trading, an increase of 20% from the average daily volume of 178,816 shares. The stock had previously closed at $4.63.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MDXH shares. Craig Hallum started coverage on MDxHealth in a research report on Thursday, July 17th. They set a "buy" rating and a $8.00 price objective on the stock. Wall Street Zen upgraded MDxHealth to a "hold" rating in a research report on Saturday, August 30th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $7.00.

MDxHealth Price Performance

The stock has a market capitalization of $219.89 million, a price-to-earnings ratio of -5.28 and a beta of 1.49. The company has a fifty day simple moving average of $3.29 and a 200 day simple moving average of $2.37. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. Equities research analysts forecast that MDxHealth SA will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. increased its holdings in MDxHealth by 10.6% in the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock worth $7,414,000 after purchasing an additional 499,992 shares in the last quarter. Perkins Capital Management Inc. increased its holdings in MDxHealth by 20.1% in the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock worth $1,678,000 after purchasing an additional 198,000 shares in the last quarter. Delta Investment Management LLC increased its holdings in MDxHealth by 459.1% in the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock worth $270,000 after purchasing an additional 156,100 shares in the last quarter. FreeGulliver LLC acquired a new position in MDxHealth during the 2nd quarter worth approximately $273,000. Finally, Castleview Partners LLC acquired a new position in MDxHealth during the 1st quarter worth approximately $48,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.